Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
New drug for relapsing multiple sclerosis.
Disease-Modifying Therapy of Pediatric Multiple Sclerosis.
Structural and Dynamical Insights on HLA-DR2 Complexes That Confer Susceptibility to Multiple Sclerosis in Sardinia: A Molecular Dynamics Simulation Study.
Three-dimensional geometries representing the retinal nerve fiber layer in multiple sclerosis, optic neuritis, and healthy eyes.
Similar genetics of adult and pediatric MS: Age is just a number.
Therapeutic compliance of first line disease-modifying therapies in patients with multiple sclerosis. COMPLIANCE Study.
Management of multiple sclerosis in adolescents - current treatment options and related adherence issues.
Corticosteroid-responsive torticollis as a presenting symptom of multiple sclerosis.
Moving to fingolimod from natalizumab in multiple sclerosis-reply.
Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease.
Neuroendocrine Responses to Transvascular Autonomic Modulation: A Modified Balloon Angioplasty in Multiple Sclerosis Patients.
Sativex-induced neurobehavioral effects: causal or concausal? A practical advice!
In-silico prediction of drug targets, biological activities, signal pathways and regulating networks of dioscin based on bioinformatics.
Exercise in the management of persons with multiple sclerosis.
Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis.
Efficacy of A Telephone-Delivered Self-Management Intervention For Persons With Multiple Sclerosis: a Randomized Controlled Trial With a One-Year Follow-Up.
Does hippotherapy effect use of sensory information for balance in people with multiple sclerosis?
Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease.
Association between age at onset of multiple sclerosis and vitamin D level-related factors.
Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation.
Clinical profile and aetiology of optic neuritis in Hospital Universiti Sains Malaysia--5 years review.
A simple score for estimating the long-term risk of fracture in patients with multiple sclerosis.
CMT4D (NDRG1 mutation): genotype-phenotype correlations.
Multiple sclerosis and restless legs syndrome: a systematic review and meta-analysis.
Alemtuzumab for multiple sclerosis.
Pages
« first
‹ previous
…
359
360
361
362
363
364
365
366
367
…
next ›
last »